Article Versions
Export Article
Case Report
Open Access Peer-reviewed

Immunoglobulin D Multiple Myeloma, a More Aggressive Subtype

Eman EL-Sawalhy1,, Najlaa Al-Sudani1, Wehbi Hnayni1, Shahina Patel2

1Department of Internal medicine, Beaumont Hospital, Dearborn, MI

2Division of Hematology & Oncology, Internal Medicine Department, Beaumont Hospital, Dearborn, MI

American Journal of Medical Case Reports. 2021, 9(5), 301-304. DOI: 10.12691/ajmcr-9-5-11
Received February 02, 2021; Revised March 05, 2021; Accepted March 14, 2021

Abstract

Immunoglobulin D (IgD) multiple Myeloma (MM) is a very rare subtype of myeloma. It accounts for only 1-2% of all MM patients. It is associated with a rapidly progressive disease and poorer outcomes compared with other MM subtypes. In this case report, we present a case of a sixty-year-old man who presented to our hospital with fatigue, anemia, thrombocytopenia, and acute renal failure. His bone marrow biopsy during admission showed 75.9% of plasma cells with significant light chain burden. He was also found to have severe immunoglobulin deficiency along with a lambda to kappa ratio was <0.01. The diagnosis of IgD MM was established, and he was started on CyBorD (Bortezomib, cyclophosphamide, and dexamethasone). Our patient also required hemodialysis for his kidney failure.

Keywords:

Immunoglobulin D, multiple myeloma, renal failure, light chain nephropathy, CyBorD
[1]  M.K. Kim, C. Suh, D.H. Lee, C.-K. Min, S.J. Kim, K. Kim, J.H. Moon, S.S. Yoon, G.-W. Lee, H.J. Kang, S.-H. Kim, C.W. Choi, H.S. Eom, J.-Y. Kwak, H.J. Kim, Y.-C. Mun, S.-M. Bang, K. Lee, H.J. Shin, J.H. Lee, Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients, Annals of Oncology, 2011, Volume 22, Issue 2, Pages 411-416.View Article  PubMed 
 
[2]  Djidjik R, Lounici Y, Chergeulaïne K, Berkouk Y, Mouhoub S, Chaib S, Belhani M, Ghaffor M. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay. Pathol Biol (Paris). 2015 Sep; 63 (4-5): 210-4.View Article  PubMed 
 
[3]  Modi J, Kamal J, Eter A, El-Sayegh S, El-Charabaty E. Immunoglobulin D Multiple Myeloma With Rapidly Progressing Renal Failure. J Clin Med Res. 2015 Aug; 7(8): 653-5.View Article  PubMed 
 
[4]  Liu J, Hu X, Jia Y, Lu J, Lee JH, Kim K, Chen W, Liu A, Liu Y, Chen Q, Zhang C, Suh C, Kim MK, Zhou F, Chng WJ, Kumar SK, Durie B, Hou J, Fu W, Du J. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia. 2020 Oct 20.View Article 
 
[5]  Zhao Q, Li F, Song P, Zhou X, An Z, Mei J, Shao J, Li H, Wang X, Guo X, Zhai Y. Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience. Cancer Commun (Lond). 2019 Sep 27; 39(1): 51.View Article  PubMed 
 
[6]  Selene II, Jose JA, Khalil MJ, Faisal MS, Malik MN. Presentation Patterns, Diagnostic Markers, Management Strategies, and Outcomes of IgD Multiple Myeloma: A Systematic Review of Literature. Cureus. 2019 Feb 4; 11(2).View Article  PubMed 
 
[7]  Farges C, Roussel M, Huynh A, Blancher A, Puissant-Lubrano B. Aggressive FLC Escape in a Patient with IgD Myeloma. Case Rep Hematol. 2015; 2015: 694730.View Article  PubMed 
 
[8]  Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, De Stefano V, La Verde G, Gentilini F, Levi A, Za T, Moscetti A, Annino L, Petti MC; Multiple Myeloma GIMEMA-Latium Region Working Group, Italy. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res. 2012 Mar 1; 31(1): 17.View Article  PubMed